Clinical characteristics of stable angina patients and their treatment strategies in real-world clinical practice. A Russian PERSPECTIVE Study (Part I)
Abstract
Aim. In a clinical and epidemiological study PERSPECTIVE, to investigate the secondary prevention implementation among stable angina patients in real-world clinical practice, and to evaluate compliance to Russian and international clinical guidelines on stable angina management. Material and methods. The study involved general practitioners and cardiologists (n=277). In the first part of the PERSPECTIVE Study, the data from out-patient medical histories (2768 patients with verified diagnosis of stable angina, SA) were analysed. Results. In SA patients, the prevalence of coronary risk factors (RFs) was high. The mean levels of blood pressure, blood lipids and lipoproteins, body mass index, and heart rate were substantially higher than the recommended target levels. At the same time, some positive changes in the clinical course of SA were observed, such as reduced incidence of angina attacks, decreased number of administered nitroglycerine tablets, and increased prevalence of Functional Class I-II SA. The qualitative changes in prescribed medications, including antianginal, anti-aggregant, and lipid-lowering agents, were also observed. Conclusion. The results obtained point to the need for further improvement of SA management in real-world clinical practice and for optimization of pharmaceutical therapy, in accordance with modern Russian and international clinical guidelines.
About the Authors
M. G. Bubnova
State Research Centre for Preventive Medicine. Moscow
Russian Federation
Russian Federation
D. M. Aronov
State Research Centre for Preventive Medicine. Moscow
Russian Federation
Russian Federation
R. G. Oganov
State Research Centre for Preventive Medicine. Moscow
Russian Federation
Russian Federation
O. G. Rudomanov
Servier Laboratories
Russian Federation
Russian Federation
A. S. Putylina
Servier Laboratories
Russian Federation
Russian Federation
References
1. 2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients with Chronic Stable Angina. A Report of the ACC/AHA Task Force on Practice Guidelines Writing Group of Develop the Focused Update of the 2002 Guidelines for the Management of Patients with Chronic Stable Angina. Circulation 2007; 116: 2762-72.
2. Диагностика и лечение стабильной стенокардии. Российские рекомендации (второй пересмотр) 2008г.
3. Оганов Р.Г., Лепахин В.К., Фитилев С.Б. и др. Особенности диагностики и терапии стабильной стенокардии в Российской Федерации (международное исследование АТР — Angina Treatment Pattern). Кардиология 2003; 5:9-15.
4. Eastaugh JL, Calvert MJ, Freemantle N. Highlighting the need for better patient care in stable angina: results of the international Angina Treatment Patterns (ATP) Survey in 7074 patients. Family Practice 2005; 22: 43-50.
5. Fox K, Garcia MAA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006.
6. Васюк Ю.А., Шальнова С.А., Школьник Е.Л., Куликов К.Г. Исследование ПРИМА: триметазидин с модифицированным высвобождением действующего вещества в лечении пациентов со стабильной стенокардией, перенесших инфаркт миокард. Эпидемиологический и клинический этапы. Кардиология 2008; 12: 1-4.
7. Шальнова С.А., Деев А.Д. Характеристика пациентов высокого риска. Результаты эпидемиологической части научно-образовательной программы ОСКАР. Кардиоваск тер профил 2006; 5 (5): 58-63.
8. Аронов Д.М., Соколова О.Ю, Гудковская Л.А. Воплощение идеи вторичной профилактики коронарной болезни сердца в реальной практике. Кардиоваскулярная терапия и профилактика 2007; 6 (1): 105-13.
9. Marzilli M, Klein WW. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized double-blind, controlled trials Coronary Artery Disease 2003, 14: 171-9
10. Маколкин В.И., Осадчий К.К. Эффективность и переносимость триметазидина при лечении стабильной стенокардии напряжения в течение 8 недель (российское исследование ТРИУМФ). Кардиология 2003; 43(6): 18-22.
11. Оганов Р.Г., Глезер М.Г. Результаты Российского исследования ПАРАЛЛЕЛЬ: Программа выявления пациентов с неэффективной терапиейбета-адреноблокаторами и сравнительной оченки эффективности добавления к терапии Предуктала МВ или изосорбида динитрата при стабильной стенокардии. Кардиология 2007; 3: 4-13.
12. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid axidation to glucose oxidation by inhibiting mitikhondrial longchain 3-ketoyacyl coenzyme A thiolase. Circulation Research 2000; 86: 580-8.
13. Szwed H, SadovskyZ, Elikovsky W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRImetazidine in POLand. Eur Heart J 2001; 22: 2267-74.
14. Аронов Д.М., Тартаковский Л.Б., Новикова Н.К. и др. Сравнительная оценка влияния физических тренировок и триметазидина. Кардиоваск тер профил 2002; 32-40.
15. El-Kady T, El-Sabban K, Gabaly M, et al. Еffects of trimetazidine on myocardial perfusion and contractileresponse of chronical myocardium in ischemic cardiomyopaty: a 24 month study. Am J Cardiovasc Drugs 2005; 5: 271-8.
16. Di Napoli P, Taccardi AA, Barsotti A. Long-term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischemic dilated cardiomyopathy. Heart 2005; 91: 161-5.
17. Di Napoli P, Di Giovanni P, Gaeta MA, et al. Trimetazidine and reduction i mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d’Abruszzo TrimetazidineTrial. J Cardiovasc Pharmacol 2007; 50: 585-9.
Review
For citations:
Bubnova M.G., Aronov D.M., Oganov R.G., Rudomanov O.G., Putylina A.S. Clinical characteristics of stable angina patients and their treatment strategies in real-world clinical practice. A Russian PERSPECTIVE Study (Part I). Cardiovascular Therapy and Prevention. 2010;9(6):47-56. (In Russ.)
Views:
604
Email this article 
